Take a look at the latest on Palatin across our media publications, posters, and presentations.
Protective Effects of 2 Melanocortin Agonists Delivered by Intravitreal Injection in Mouse Models of Retinopathy
Melanocortins have a wide range of activities, including inhibition of leukocyte activation, inhibition of inflammation, and protection of tissues1-3 The melanocortin system plays a key role in promoting resolution of the inflammatory process
Efficacy and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of Subjects With Dry Eye Disease
This is a multifactorial inflammatory disease affecting multiple areas in the eye. Existing therapies are often inadequate due to poor efficacy, adverse effects, or poor tolerability.
Bremelanotide Provides Meaningful Treatment Benefits for Premenopausal Women With Hypoactive Sexual Desire Disorder
Bremelanotide, a melanocortin receptor agonist and an analog of the endogenous neuropeptide Œ±-melanocortin stimulating hormone, has been approved in the US for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The RECONNECT studies demonstrated that subcutaneous self-administration of bremelanotide significantly improved sexual desire and decreased personal distress in premenopausal women with HSDD.
Female sexual dysfunctions (FSD) include a range of distressing, multifactorial conditions, such as dysfunctions of sexual interest/desire, sexual arousal, a delay in or absence of orgasm, and sexual pain. The most common sexual concern expressed by women is diminished or lack of desire for sexual activity, which may be diagnosed as hypoactive sexual desire disorder (HSDD), if the lack of desire causes distress. Bremelanotide (BMT), a novel cyclic 7-amino acid melanocortin-receptor agonist with the potential to modulate neural pathways involved in sexual response, is being developed to treat FSD.
Carl Spana, Andrew W. Taylor, David G. Yee, Marie Mahklina, Wei Yang, John Dodd, Presented at TIDES: Oligonucleotide and Peptide Therapeutics 2018
Safety and Efficacy of Bremelanotide for HSDD in Women: RECONNECT Study Open-Label Extension Phase Results
Results from the Core Study Phase have been reported previously. This presentation includes long-term safety and efficacy results from the RECONNECT Open-Label Extension (OLE) Study Phase.
Describes how bremelanotide, an analog of the naturally occurring peptide Œ±-melanocyte-stimulating hormone (Œ±-MSH), acts on the physiological and neurobiological components of female sexual function to improve sexual arousal and desire in women with HSDD.
Bremelanotide for Hypoactive Sexual Desire Disorder: Age and Weight Subgroup Efficacy Analyses From the RECONNECT Studies
Analyses of the co-primary and key secondary endpoints were performed as exploratory analyses for the age and weight subgroups of the RECONNECT studies to assess the consistency of BMT‚Äôs effect.
Exit Survey of Women With Hypoactive Sexual Desire Disorder Treated With Bremelanotide in the RECONNECT Studies Demonstrated Meaningful Treatment Benefits
The objective of this survey was to understand the impact of HSDD in premenopausal women and to provide a deeper understanding of the effect and impact/meaningfulness of BMT beyond clinical trial results.
Development of a Patient-Centric Exit Study to Contextualize and Assess Meaningfulness of a Potential Treatment for Hypoactive Sexual Desire Disorder (HSDD)
Female sexual dysfunctions (FSD) include a group of conditions characterized by physiological, psychological, and social components. The most common sexual concern expressed by women with FSD is diminished or lack of desire for sexual activity. When accompanied by distress, this may be diagnosed as hypoactive sexual desire disorder (HSDD). Bremelanotide (BMT; PT-141) is an investigational drug being developed as a treatment for HSDD in premenopausal women.